

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Chong-Oh KIM et al.

Appln. No: 10/635,615

Filed: August 7, 2003

For : RADIOACTIVE MAGNETIC FLUIDS FOR TREATMENT OR DIAGNOSIS OF

CANCER, PROCESS FOR PREPARING THEM AND USE THEREOF

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants hereby bring the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the specification.

U.S. Patent No. 5,921,244, which is cited and discussed in the specification beginning on page 3, line 11;

U.S. Patent No. 4,957,481, which is cited and discussed in the specification beginning on page 3, line 15;

Urs HAFELI et al., "Radiolabeling of Magnetic Particles with Rhenium-188 for Cancer Therapy", Journal of Magnetism and Magnetic Materials, Vol. 225, pp. 73-78 (2001), which is cited and discussed in the specification beginning on page 6, line 23;

P24028.A01

Ch. ALEXIOU et al., "Magnetic Drug Targeting: Biodistribution and Dependency on

Magnetic Field Strength", Journal of Magnetism and Magnetic Materials, Vol. 252, pp. 363-366

(2002), which is cited and discussed in the specification beginning on page 7, line 4; and

Yuqiang HUANG et al., "Preparation of nanometric Cu_rFe_{1-r}OFe₂O₃ for Treatment of

Tumor", Journal of Applied Physics, Vol. 93, No. 10, pp. 8444-8446 (2003).

Copies of the above-noted documents are enclosed together with a duly completed Form

PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to

make them of record in this application by initialing in the appropriate spaces on the Form PTO-

1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-

1449 with the next communication from the U.S. Patent and Trademark Office.

In accordance with 37 C.F.R. § 1.97(b)(1), this Information Disclosure Statement is filed

within three months of the filing date of the application. Accordingly, no fees are required.

Should there be any questions, the Examiner is invited to contact the undersigned at the

below listed telephone number.

Respectfully submitted,

Chong-Oh KIM et al.

Bruce H. Bernstein Reg. No. 29,027 Jano. 33, 894

November 6, 2003

GREENBLUM & BERNSTEIN, P.L.C.

1950 Roland Clarke Place Reston, VA 20191

(703) 716-1191

2

Ý.

150

	I HOA a a	ā
Form PTO-1449	E.	3
	TRADE	MARIE

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. P24028

Serial No. 10/635,615

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicants
Chong-Oh KIM et al.

Filing Date August 7, 2003 Group Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		5	9	2	1	2	4	4	07/13/99	CHEN et al.				
		4	9	5	7	4	8	1	09/18/90	GATENBY				
	1												-	
	1													-
	7	٦												
	1	Ī												
		Ì												
					Γ									
	\sqcap													
									FO	REIGN PATENT DOCUMENTS	3			
		DOCUMENT NUMBER					MB	ER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL YES	ATION NO
						от	HE	R DC	CUMENTS	G (Including Author, Title, Date, F	Pertinent Pages,	Etc.)		
		1	U	rs H.	AFE	ELLe	et al	. "Ra	diolabeling o	of Magnetic Particles with Rhenium	n-188 for Cancer	Therapy". Journal	of Magnetis	m and

- Urs HAFELI et al., "Radiolabeling of Magnetic Particles with Rhenium-188 for Cancer Therapy", Journal of Magnetism and Magnetic Materials, Vol. 225, pp. 73-78 (2001).
 - 2 Ch. ALEXIOU et al., "Magnetic Drug Targeting: Biodistribution and Dependency on Magnetic Field Strength", Journal of Magnetism and Magnetic Materials, Vol. 252, pp. 363-366 (2002).
 - Yuqiang HUANG et al., "Preparation of nanometric Cu_χFe_{1.χ}OFe₂O₃ for Treatment of Tumor", Journal of Applied Physics, Vol. 93, No. 10, pp. 8444-8446 (2003).

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.